PDAOAI PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today opened access to PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful signals from large, complex biomedical datasets without training bespoke large language models (LLMs) on proprietary d ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 大量流行病学证据表明， 外部风险因素 （例如 肥胖、糖尿病、创伤、慢性感染、炎症或免疫激活 ） 对 散发性神经退行性疾病 的发生发挥着关键作用，但这些 因素如何传递到神经退行性疾病中那些特征明确的神经病理学或关键的细胞和分子特征的确切分子机制，目前仍不清楚。 我们已知，上述外部风险因素不会直接导致神经退行性疾病，但长期接触嗜神经病毒与某些疾病的发生有关，例如 流感病毒 与 帕金森病 ， 疱疹病毒 与包括 阿 尔茨海默病 在内的痴呆症等。因此，研究人员推测，可能是病毒与关键宿主细胞因子之间的分子相互作用，或者病毒通过免疫激活或其引发的细胞反应，间接影 响了神经退行性疾病。 2025 年 12 月 18 日，德国 杜塞尔多夫大学的研究人员在 Cell 子刊 Cell Reports Medicine 上发表了题为： Oxidized MIF is an Alzheimer's disease drug target relaying external risk factors to tau pathology 的研究论文。 该研究表明， 氧化型巨噬细胞移动抑制因子 （oxM ...

The Dana-Farber Cancer Institute has agreed to pay $15 million to settle fraud allegations, including its scientists’ use of inaccurate or altered data and images in grant-funded biomedical research https://t.co/ZRBLEePbdl ...

在生命科学研究与基因治疗转化的赛道上， 基因递送 是当之无愧的核心环节 —— 它就像一座 " 桥梁 " ， 负责将核酸分子 （例如 DNA 、 RNA 、 RNP 等） 精准送进细胞内，实现基因的过表达、敲低或编辑，从 而帮助科研人员解析基因功能、探索疾病机制。但长久以来，这座 " 桥梁 " 却一直存在诸多 " 通行障碍 "。 基因递送的 " 老难题 " ：传统工具的局限性 一条不同的技术路线：从基础生物学出发的重新思考 针对以上困境， 西湖大学 联合 西湖凝聚体 团队，自主研发出全球首创的 ProteanFect 基因递送系统 ， 构建了 非病毒、非脂质体、非电转 的全新递送路径 。其核心创新点在于 " 仿生内源蛋白凝聚体 " 的设计 思路：该系统模拟细胞内源性蛋白液液相分离特性，通过仿生机制实现核酸分子的高效包裹与递送。这种 独特的递送模式，既规避了病毒载体的免疫原性风险，又摆脱了脂质体对细胞类型的适配限制，同时避免 了物理手段对细胞的损伤，为基因递送搭建起了一条更安全、更通畅的 " 新桥梁 " 。 从 递送类型 来看， ProteanFect 可实现 mRNA/ 质粒过表达、 siRNA 基因敲低、 C ...

【导读】尽管黑色素瘤细胞通常表达大量突变蛋白，但反应性 T 细胞的浸润却很少能引发根除肿瘤的免疫反应。 12月15日，以色列特拉维夫大学等单位学者在期刊《Cell》上发表了研究论文，题为"HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion"，本研究中，研究人员发现，黑色素瘤细胞分泌的大细胞外囊泡（即黑素体）表面 装饰有主要组织相容性复合体（MHC）分子，这些分子通过 T 细胞受体（TCR）刺激 CD8+ T 细胞，导致 T 细胞功能障碍和 细胞凋亡。免疫肽组学和 T 细胞受体测序（TCR-seq）分析表明，这些黑素体携带与 MHC 结合的肿瘤相关抗原，其亲和力和 免疫原性更高，与肿瘤细胞原位竞争直接的 TCR-MHC 相互作用。对黑色素瘤患者的活检分析证实，黑素体捕获浸润淋巴细 胞，诱导部分活化，并降低 CD8+ T 细胞的细胞毒性。在体内抑制黑素体分泌显著减少了肿瘤的免疫逃逸。这些发现表明， MHC 输出保护黑色素瘤免受 T 细胞的细胞毒性作用。本研究揭示了一种新的免疫逃逸机制，并提出了增强肿瘤免疫的 ...

SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced its financial results for the six months ended June 30, 2025. "Although our revenue decreased and our net loss increased compared with the same period last year, the first six months of 2025 allowed us to achieve significant ad ...

DALLAS--(BUSINESS WIRE)--Impossible Dream Machine Partners with Parkland Center for Clinical Innovation (PCCI). ...

排版丨水成文 可转座元件 （ Transposable element， TE） 占据了近一半的基因组，并推动了发育创新，然而， 长末端重复序列 （Long Terminal Repeat，LTR） 是某些 可转座元件 两端的 DNA 重复序列，它们对元件的复制、整合和基因 表达调控发挥着关键作用。然而，我们对于 LTR 沉默的机制仍不完全清楚。 2025 年 10 月 29 日，同济大学 高绍荣 院士、 高亚威 教授、 王译萱 教授，北京大学 刘君 教授团队合作 （ 朱学昊、常展赫、肖维德为论文共同第一作者 ） ，在 Cell Stem Cell 期刊 发表了题： N6-methyladenosine on L1PA Governs the Trans-silencing of LTRs and Restrains totipotency in Naïve Human Embryonic Stem Cells 的研究论文。 编辑丨王多鱼 METTL3 缺失可使 naïve 人类胚胎干细胞 （hESC） 获得全能性并激活 8-细胞转录组； L1PA 上的 m6A 修饰的去除激活了 8-细胞 LTR，并诱导 n ...

Core Insights - Cuprina Holdings has signed a Memorandum of Understanding (MOU) with Singapore Biowaste Solutions to explore the integration of its medical waste recycling technology into SBS's waste management facility in Singapore [1][2][3] Company Overview - Cuprina Holdings is a biomedical company focused on developing and marketing products for chronic wounds, infertility, and cosmeceuticals [1][6] - Singapore Biowaste Solutions is recognized as Singapore's most advanced provider for biomedical waste disposal and management [7] Collaboration Details - The collaboration aims to reduce reliance on incineration and landfilling, enhance recycling efficiency, and unlock new revenue streams from recycled materials [2][5] - Cuprina will provide technical expertise, training, and support for a feasibility study and pilot program at SBS's facility [3][4] - SBS will contribute operational data, facility access, and regulatory support to ensure compliance with Singapore's environmental standards [4] Technology and Innovation - Cuprina's technology involves a high-temperature steam process known as autoclaving, which sterilizes, decontaminates, and recycles plastic-based medical waste into high-value resins [3] - This technology has been developed under the oversight of the United Nations Industrial Development Organization (UNIDO) and the Global Environment Facility (GEF) [3] Future Prospects - The companies plan to develop revenue-sharing models for the integrated process and explore expansion opportunities across Southeast Asia [5] - Cuprina's CEO expressed optimism that the integrated recycling technology could secure necessary regulatory approvals and commence operations by the end of 2026 [5]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Bio-Rad Laboratories, with a focus on how actual results compare to estimates, which could significantly impact stock price [1][2]. Earnings Expectations - Bio-Rad is expected to report quarterly earnings of $2.30 per share, reflecting a year-over-year increase of 14.4%. Revenues are projected to be $651.42 million, up 0.3% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial estimates during this period [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate matches the Zacks Consensus Estimate for Bio-Rad, resulting in an Earnings ESP of 0%. The stock currently holds a Zacks Rank of 4, complicating predictions for an earnings beat [12]. Historical Performance - In the last reported quarter, Bio-Rad exceeded expectations by posting earnings of $2.61 per share against an expected $1.93, achieving a surprise of 35.23%. Over the last four quarters, the company has beaten consensus EPS estimates three times [13][14]. Conclusion - While Bio-Rad does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17].